| [1] |
Kim DS, Kim BC, Daily JW, et al. High genetic risk scores for impaired insulin secretory capacity doubles the risk for type 2 diabetes in Asians and is exacerbated by Western-type diets[J]． Diabetes Metab Res Rev， 2018， 34(1)：e2944.DOI： 10.1002/dmrr.2944.
|
| [2] |
Meikle PJ， Summers SA.Sphingolipids and phospholipids in insulin resistance and related metabolic disorders[J]． Nat Rev Endocrinol， 2017， 13(2): 79-91.DOI： 10.1038/nrendo.2016.169.
|
| [3] |
Saeedi P， Petersohn I， Salpea P，et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045：results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]． Diabetes Res Clin Pract， 2019(157)：107843.DOI： 10.1016/j.diabres.2019.107843.
|
| [4] |
Vasiliauskaité-Brooks I, Sounier R, Rochaix P, et al. Structural insights into adiponectin receptors suggest ceramidase activity[J]． Nature， 2017， 544(7648)：120-123.DOI： 10.1038/nature21714.
|
| [5] |
Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy[J]． Nat Rev Cancer， 2018， 18(1)：33-50.DOI： 10.1038/nrc.2017.96.
|
| [6] |
Hannun YA， Obeid LM.Sphingolipids and their metabolism in physiology and disease[J]． Nat Rev Mol Cell Biol， 2018， 19(3)：175-191.DOI： 10.1038/nrm.2017.107.
|
| [7] |
Galadari S， Rahman A， Pallichankandy S，et al.Role of ceramide in diabetes mellitus: evidence and mechanisms[J]． Lipids Health Dis， 2013(12)：98.DOI： 10.1186/1476-511X-12-98.
|
| [8] |
Woo CY， Baek JY， Kim AR，et al.Inhibition of ceramide accumulation in podocytes by myriocin prevents diabetic nephropathy[J]． Diabetes Metab J， 2020， 44(4)：581-591.DOI: 10.4093/dmj.2019.0063.
|
| [9] |
Raichur S, Brunner B, Bielohuby M, et al. The role of C16：0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach[J]． Mol Metab， 2019(21): 36-50.DOI： 10.1016/j.molmet.2018.12.008.
|
| [10] |
Filippatou AG, Moniruzzaman M, Sotirchos ES, et al. Serum ceramide levels are altered in multiple sclerosis[J]． Mult Scler， 2021， 27(10)：1506-1519.DOI： 10.1177/1352458520971816.
|
| [11] |
Garić D， De Sanctis JB， Shah J，et al.Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases：the importance of side chain[J]． Prog Lipid Res， 2019(74)：130-144.DOI： 10.1016/j.plipres.2019.03.001.
|
| [12] |
Chakravarthy H， Navitskaya S， O'Reilly S ，et al.Role of acid sphingomyelinase in shifting the balance between proinflammatory and reparative bone marrow cells in diabetic retinopathy[J]． Stem Cells， 2016， 34(4)：972-983.DOI： 10.1002/stem.2259.
|
| [13] |
Pant DC， Aguilera-Albesa S， Pujol A．Ceramide signalling in inherited and multifactorial brain metabolic diseases[J]． Neurobiol Dis， 2020(143)：105014.DOI： 10.1016/j.nbd.2020.105014.
|
| [14] |
Morad SA， Cabot MC.Ceramide-orchestrated signalling in cancer cells[J]． Nat Rev Cancer， 2013， 13(1): 51-65.DOI： 10.1038/nrc3398.
|
| [15] |
Castro BM， Prieto M， Silva LC.Ceramide: a simple sphingolipid with unique biophysical properties[J]． Prog Lipid Res， 2014(54)：53-67.DOI: 10.1016/j.plipres.2014.01.004.
|
| [16] |
Yaribeygi H， Bo S， Ruscica M，et al.Ceramides and diabetes mellitus：an update on the potential molecular relationships[J]． Diabet Med， 2020， 37(1)：11-19.DOI: 10.1111/dme.13943.
|
| [17] |
Park WJ, Song JH, Kim GT, et al. Ceramide and Sphingosine 1-phosphate in liver diseases[J]． Mol Cells， 2020， 43(5)：419-430.DOI： 10.14348/molcells.2020.0054.
|
| [18] |
Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling[J]． Cell Signal， 2008， 20(6): 1010-1018.DOI： 10.1016/j.cellsig.2007.12.006.
|
| [19] |
Chaurasia B, Tippetts TS, Mayoral Monibas R, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis[J]． Science， 2019， 365(6451): 386-392.DOI： 10.1126/science.aav3722.
|
| [20] |
Xia QS， Lu FE， Wu F，et al.New role for ceramide in hypoxia and insulin resistance[J]． World J Gastroenterol， 2020， 26(18): 2177-2186.DOI： 10.3748/wjg.v26.i18.2177.
|
| [21] |
Mandal N， Grambergs R， Mondal K，et al.Role of ceramides in the pathogenesis of diabetes mellitus and its complications[J]． J Diabetes Complications， 2021， 35(2)：107734.DOI： 10.1016/j.jdiacomp.2020.107734.
|
| [22] |
Baranowski M， Blachnio-Zabielska A， Hirnle T，et al.Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide[J]． J Lipid Res， 2010， 51(1): 74-80.DOI： 10.1194/jlr.M900002-JLR200.
|
| [23] |
Sugimoto M， Shimizu Y， Zhao S，et al.Characterization of the role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice[J]． Biochim Biophys Acta， 2016， 1861(8 Pt A)：688-702.DOI： 10.1016/j.bbalip.2016.04.019.
|
| [24] |
Holland WL， Brozinick JT， Wang LP，et al.Inhibition of ceramide synthesis ameliorates glucocorticoid-，saturated-fat-，and obesity-induced insulin resistance[J]． Cell Metab， 2007， 5(3)：167-179.DOI： 10.1016/j.cmet.2007.01.002.
|
| [25] |
Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy[J]． Nephrol Dial Transplant， 2009， 24(11)：3288-3296.DOI： 10.1093/ndt/gfp302.
|
| [26] |
Hilvo M， Salonurmi T, Havulinna AS, et al. Ceramide stearic to palmitic acid ratio predicts incident diabetes[J]． Diabetologia， 2018， 61(6)：1424-1434.DOI： 10.1007/s00125-018-4590-6.
|
| [27] |
Stitt AW， Lois N， Medina RJ，et al.Advances in our understanding of diabetic retinopathy[J]． Clin Sci(Lond)， 2013， 125(1)：1-17.DOI： 10.1042/CS20120588.
|
| [28] |
Brownlee M．Biochemistry and molecular cell biology of diabetic complications[J]． Nature， 2001， 414(6865)：813-820.DOI： 10.1038/414813a.
|
| [29] |
Opreanu M， Tikhonenko M， Bozack S，et al.The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models[J]． Diabetes， 2011， 60(9)：2370-2378.DOI： 10.2337/db10-0550.
|
| [30] |
Levitsky Y， Hammer SS， Fisher KP，et al.Mitochondrial ceramide effects on the retinal pigment epithelium in diabetes[J]． Int J Mol Sci， 2020， 21(11)：3830.DOI： 10.3390/ijms21113830.
|
| [31] |
Molitch ME， Adler AI， Flyvbjerg A，et al.Diabetic kidney disease: a clinical update from kidney disease：improving global outcomes[J]． Kidney Int， 2015， 87(1)：20-30.DOI： 10.1038/ki.2014.128.
|
| [32] |
Wada J， Makino H．Inflammation and the pathogenesis of diabetic nephropathy[J]． Clin Sci(Lond)， 2013， 124(3)：139-152.DOI： 10.1042/CS20120198.
|
| [33] |
Lang F， Ullrich S， Gulbins E．Ceramide formation as a target in beta-cell survival and function[J]． Expert Opin Ther Targets， 2011， 15(9)：1061-1071.DOI： 10.1517/14728222.2011.588209.
|
| [34] |
Choi SR, Lim JH, Kim MY, et al. Adiponectin receptor agonist AdipoRon decreased ceramide，and lipotoxicity，and ameliorated diabetic nephropathy[J]． Metabolism， 2018(85)：348-360.DOI： 10.1016/j.metabol.2018.02.004.
|
| [35] |
Holland WL， Xia JY， Johnson JA，et al.Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis[J]． Mol Metab， 2017， 6(3)：267-275.DOI： 10.1016/j.molmet.2017.01.002.
|
| [36] |
Sas KM， Nair V， Byun J，et al.Targeted lipidomic and transcriptomic analysis identifies dysregulated renal ceramide metabolism in a mouse model of diabetic kidney disease[J]． J Proteomics Bioinform， 2015(14): 2.DOI： 10.4172/jpb.S14-002.
|
| [37] |
Morita Y， Kurano M， Sakai E，et al.Analysis of urinary sphingolipids using liquid chromatography-tandem mass spectrometry in diabetic nephropathy[J]． J Diabetes Investig， 2020， 11(2)：441-449.DOI： 10.1111/jdi.13154.
|
| [38] |
Klein RL， Hammad SM， Baker NL，et al.Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes[J]． Metabolism， 2014， 63(10)：1287-1295.DOI： 10.1016/j.metabol.2014.07.001.
|
| [39] |
Peterson LR， Jiang X， Chen L，et al.Alterations in plasma triglycerides and ceramides：links with cardiac function in humans with type 2 diabetes[J]． J Lipid Res， 2020， 61(7)：1065-1074.DOI： 10.1194/jlr.RA120000669.
|
| [40] |
Yu J， Pan W， Shi R，et al.Ceramide is upregulated and associated with mortality in patients with chronic heart failure[J]． Can J Cardiol， 2015， 31(3)：357-363.DOI： 10.1016/j.cjca.2014.12.007.
|
| [41] |
Wang DD， Toledo E， Hruby A，et al.Plasma ceramides，mediterranean diet，and incident cardiovascular disease in the predimed trial (Prevención con Dieta Mediterránea)[J]． Circulation， 2017， 135(21): 2028-2040.DOI： 10.1161/CIRCULATIONAHA.116.024261.
|
| [42] |
Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy[J]． Cochrane Database Syst Rev， 2012， 6(6)：CD007543.DOI： 10.1002/14651858.CD007543.pub2.
|
| [43] |
Callaghan BC， Gallagher G， Fridman V，et al.Diabetic neuropathy: what does the future hold？[J]． Diabetologia， 2020， 63(5)：891-897.DOI： 10.1007/s00125-020-05085-9.
|
| [44] |
Zuellig RA， Hornemann T， Othman A，et al.Deoxysphingolipids，novel biomarkers for type 2 diabetes，are cytotoxic for insulin-producing cells[J]． Diabetes， 2014， 63(4)：1326-1339.DOI： 10.2337/db13-1042.
|
| [45] |
Hammad SM, Baker NL, El Abiad JM, et al. Increased plasma levels of select Deoxy-ceramide and ceramide species are associated with increased odds of diabetic neuropathy in type 1 diabetes: a pilot study[J]． Neuromolecular Med， 2017， 19(1)：46-56.DOI： 10.1007/s12017-016-8423-9.
|
| [46] |
Langeslag M， Kress M．The ceramide-S1P pathway as a druggable target to alleviate peripheral neuropathic pain[J]． Expert Opin Ther Targets， 2020， 24(9): 869-884.DOI： 10.1080/14728222.2020.1787989.
|
| [47] |
Li C， Li JN， Kays J，et al.Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3[J]． J Neuroinflammation， 2015(12)：70.DOI： 10.1186/s12974-015-0286-8.
|